These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17241749)

  • 1. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer.
    D'Ambrosio DJ; Hanlon AL; Al-Saleem T; Feigenberg SJ; Horwitz EM; Uzzo RG; Pollack A; Buyyounouski MK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1082-7. PubMed ID: 17241749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
    Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy.
    Buyyounouski MK; Hanlon AL; Horwitz EM; Pollack A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):59-66. PubMed ID: 17919840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
    D'Ambrosio DJ; Ruth K; Horwitz EM; Chen DY; Pollack A; Buyyounouski MK
    Urology; 2008 May; 71(5):938-41. PubMed ID: 18279939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
    Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
    Zelefsky MJ; Ben-Porat L; Scher HI; Chan HM; Fearn PA; Fuks ZY; Leibel SA; Venkatraman ES
    J Clin Oncol; 2005 Feb; 23(4):826-31. PubMed ID: 15681527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer.
    Abramowitz MC; Li T; Buyyounouski MK; Ross E; Uzzo RG; Pollack A; Horwitz EM
    Cancer; 2008 Jan; 112(1):55-60. PubMed ID: 17968996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
    Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer.
    Jacob R; Hanlon AL; Horwitz EM; Movsas B; Uzzo RG; Pollack A
    Cancer; 2004 Feb; 100(3):538-43. PubMed ID: 14745870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?
    Khuntia D; Reddy CA; Mahadevan A; Klein EA; Kupelian PA
    Cancer; 2004 Mar; 100(6):1283-92. PubMed ID: 15022298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement.
    Jacob R; Hanlon AL; Horwitz EM; Movsas B; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):695-701. PubMed ID: 15708247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer radiotherapy dose response: an update of the fox chase experience.
    Pollack A; Hanlon AL; Horwitz EM; Feigenberg SJ; Uzzo RG; Hanks GE
    J Urol; 2004 Mar; 171(3):1132-6. PubMed ID: 14767286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
    Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
    Zapatero A; Mínguez R; Nieto S; Martín de Vidales C; García-Vicente F
    Eur Urol; 2009 Apr; 55(4):902-9. PubMed ID: 18485578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer.
    Kupelian PA; Ciezki J; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):16-22. PubMed ID: 17996382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.